Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Takes Dramatic Step to Curb TCM Speculation

publication date: Jul 18, 2011
China’s National Development and Reform Commission (NDRC), which has responsibility for controlling prices in China, decided on a dramatic course of action to lower the high cost of TCM raw materials. The NDRC told anyone who has a supply of codonopsis pilosula, an important TCM herb more popularly known as radix, that they must sell their supplies – and then set a low price as the ceiling at which the transactions must take place. To show that it means business, the NDRC ordered the worst offenders to sell their stockpiles within one week. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital